Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide

Infection, Supplement

Volumn 33, Issue 2, 2005, Pages 36-43

  Dalhoff, A ^a   Schubert, S ^a   Ullmann, U ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; TELITHROMYCIN; ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; EFFUSION; HAEMOPHILUS INFLUENZAE; LUNG FLUID; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; NOSE SECRETION; OTITIS; PH; PKA; PLEURA FLUID; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; ACIDITY; ANTIMICROBIAL ACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; IN VITRO STUDY;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HYDROGEN-ION CONCENTRATION; MACROLIDES; MICROBIAL SENSITIVITY TESTS;

EID: 31444451710     PISSN: 01732129     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-005-8206-y     Document Type: Article

References (65)

1. Milne MD, Scribner BH, Crawford MA: Non-ionic diffusion and the excretion of weak acids and bases. Am J Med 1958; 24: 709-729.
2. Carlier MB, Zenebergh A, Tulkens PM: Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J Antimicrob Chemother 1987; 20 (Suppl. B): 47-56.
3. McFarland JW, Berger CM, Froshauer SA: Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. J Med Chem 1997; 40: 1340-1346.
4. Retsema JA, Brennan LA, Girard AE: Effects of environmental factors on the in vitro potency of azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10: 834-842.
5. Retsema JA: Susceptibility and resistance emergence studies with macrolides. Int J Antimicrob Agents 1999; 11 (Suppl. 1): S15-21; discussion S31-32.
6. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernades PB: Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother 1988; 32: 1710-1719.
7. Dubreuil L: In-vitro comparison of roxithromycin and erythromycin against 900 anaerobic bacterial strains. J Antimicrob Chemother 1987; 20 (Suppl. B): 13-19.
8. Fiese EF, Steffen SH: Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother 1990; 25 (Suppl. A): 39-47.
9. Gladue RP, Snider ME: Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother 1990; 34: 1056-1060.
10. Bryskier A: New research in macrolides and ketolides since 1997. Expert Opin Investig Drugs 1997; 8: 1171-1194.
11. Champney WS, Tober CL: Structure-activity relationships for six ketolide antibiotics. Curr Microbiol 2001; 42: 203-210.
12. Dalhoff A: Pharmacokinetics of selected antibacterial agents. Antibiot Chemother 1998; 49: 1-148.
13. Sorgel F, Kinzig M: Pharmacokinetics of gyrase inhibitors, Part 1: Basic chemistry and gastrointestinal disposition. Am J Med 1993; 94: 44S-55S.
14. Petersen U, Bremm KD, Dalhoff A, Endermann R, Heilmann W, Krebs A, Schenke T: The synthesis and in vitro and in vivo antibacterial activity of moxiflocaxin (BAY 12-8039), a new 8-methioxyquinolone. In: Adam D, Finch R (eds): Moxifloxacin in practice, vol. 1. Maxim Medical, Oxford 1999, pp 13-26.
15. Deutsches Institut für Normung, e.V. Methoden zur Empfindlichkeitsprüfung von bakteriellen Krankheitserregren (Ausser Mykobakterien) gegen Chemotherapeutika-Teil 8 Mikrodilution;Allgemeine methodenspezifische Anforderungen. Beuthj Verlag GmbH, Berlin 2000.
16. Andreasen JJ, Nissen B, Hartzen SH: Influence of carbon-dioxide tension and medium buffer concentration on medium pH and MIC values of erythromycin for Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 25923 in a micro-aerobic atmosphere. Acta Pathol Microbiol Immunol Scand [B] 1987; 95: 253-255.
17. Brueggemann AB, Kugler KC, Doern GV: In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 1997; 41: 1594-1597.
18. Carenfelt C; Lundberg C: Purulent and non-purulent maxillary sinusal secretions with respect to pO2, pCO2 and pH. Acta Otolaryngol 1977; 84: 138-144.
19. Tate S, MacGregor G, Davis M, Greening AP: Airways in cystic fibrosis are acidified: detection by exhaled breath condensate. Thorax 2002; 57: 926-929.
20. Bodem CR, Lampton LM, Miller DP: Endobronchial pH. Relevance of aminoglycoside activity in gram-negative bacillary pneumonia. Am Rev Respir Dis 1983; 127: 39-41.
21. Guerrin F, Robin H, Lampert P: Effects of hypoxia-hypercapnia. J Physiol 1969; 61: 305-306.
22. Guerrin F, Voisin C, Macquet V: Apport de la pH metrie bronchique in situ. Prog Respir Res 1970; 6: 372-383.
23. Blaisdell CJ, Edmonds RD, Wang XT: pH-regulated chloride secretion in fetal lung epithelia. Am J Physiol Lung Cell Mol Physiol 2000; 278: L1248-1255.
24. Jayaraman S, Joo NS, Reitz B: Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na(+)] and pH but elevated viscosity. Proc Natl Acad Sci U S A 2001; 98: 8119-8123.
25. Schubel F: [pH-measurements in vivo and microbial determination in chronic mucosal hyperplasia of the maxillary sinus and nose]. Z Laryngol Rhinol Otol 1968; 47: 692-696.
26. Sakakura Y, Majima Y, Yoshii S: Nasal secretion from normal subjects. Auris Nasus Larynx, 1979; 6: 71-78.
27. Burmeister CC: A study of the hydrogen-ion concentration, nitrogen content and viscosity of nasal secretions. Ann Otol Rhinol Laryngol 1933; 42: 1041-1057.
28. Nuutinen J, Torkkeli T, Penttila I: The pH of secretions in sinusitis and otitis media. J Otolaryngol 1993; 22: 79-82.
29. Malosov VA, Plotnikova NE: The protein composition and pH of nasal secreta in patients suffering from rhinitis. Vestn Otorinolaringol 1971; 33: 20-25.
30. Breuninger H: [on the Physical-Chemical Behavior of the Nasal Mucus]. Arch Ohren Nasen Kehlkopfheilkd 1964; 184: 133-138.
31. Anderson H: Note on some changes in the hydrogen ion concentration of nasal mucus. Ann Otol Rhinol Laryngol 1934; 43: 47-49.
32. Fabricant ND: Significance of the pH of nasal secretions. Arch Otolaryngol 1941; 34: 150-163.
33. Brown RB, Weinstein L: Lower respiratory tract infection. In: Feign RD, Cherry JD (eds): Pleural effusions. Textbook of pediatric infectious diseases, vol. 1. Saunders Com, Philadelphia 1987, pp 340-346.
34. Heffner JE, Brown LK, Barbieri C, DeLeo JM: Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. Am J Respir Crit Care Med 1995; 151: 1700-1708.
35. Light RW, MacGregor MI, Ball WC Jr, Luchsinger PC: Diagnostic significance of pleural fluid pH and PCO2. Chest 1973; 64: 591-596.
36. Light RW, Girard WM, Jenkinson SG, George RB: Parapneumonic effusions. Am J Med 1980; 69: 507-512.
37. Potts DE, Levin DC, Sahn SA: Pleural fluid pH in parapneumonic effusions. Chest 1976; 70: 328-331.
38. Fine MJ, Singer DE, Hanusa BH, Lave JR, Kapoor WN: Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. Am J Med 1993; 94: 153-159.
39. Biedenbach DJ, Jones RN, Lewis MT, Croco MAT: Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results. Diagn Microbiol Infect Dis 1999; 33: 275-282.
40. Fuchs PC, Barry A, Brown SD: Influence of variations in test methods on susceptibility of Haemophilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin. J Clin Microbiol 2001; 39: 43-46.
41. Gerardo SH, Citron DM, Claros MC, Goldstein EJC: Comparison of Etest to brothmicrodilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. Antimicrob Agents Chemother 1996; 40: 2413-2415.
42. Johnson J, Bouchillon S, Pontani D: The effect of carbon dioxide on susceptibility testing of azithromycin, clarithromycin and roxithromycin against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes by broth microdilution and the Etest: Artemis Project-first-phase study. Clin Microbiol Infect 1999; 5: 327-330.
43. Ramer NC, McDaniel DF, Johnson PM, Shortridge D, Ma Z, Or Y, Flamm RK: Effect of pH and media on the in vitro minimal inhibitory concentration of ABT-773. 39th ICAAC, 1999, San Francisco. Abstr. no 2143.
44. Rodloff A, Grimm H, Schmalreck A, Pfruender D: Empfindlichkeitsprü fung von Haemophilus influenzae und Streptococcus pneumoniae. Chemotherapie Journal 2003; 12: 109-114.
45. Seral C, Van Bambeke F, Tulkens PM: Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother 2003; 47: 2283-2292.
46. Maskell JP, Sefton AM, Cannell H, Kerawala C, Seymour A, Sun ZM, Williams JD: Predominance of resistant oral streptococci in saliva and the effect of a single course of josamycin or erythromycin. J Antimicrob Chemother 1990; 26: 539-548.
47. Kluytmans J, Berg H, Tjhie J, Peeters M, vanKeulen P, Stobberingh E: A short course of clarithromycin causes substantial development of resistance in oropharyngeal flora: a double-blind placebo controlled study. 43rd ICAAC, 2003, Chicago.
48. Edlund C, Alvan G, Barkholt L, Vacheron F, Nord CE: Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J Antimicrob Chemother 2000; 46: 741-749.
49. Leach AJ, Shelby-James TM, Mayo M, Gratten M, Laming AC, Currie BJ, Mathews JD: A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 1997; 24: 356-362.
50. Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC: In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44: 414-417.
51. Felmingham D: Microbiological profile of telithromycin, the first ketolide antibacterial, telithromycin. Clin Microbiol Infect 2001; 7 (Suppl. 3): 2-10.
52. Leclercq R: Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin. J Antimicrob Chemother 2001; 48 (Suppl. T1): 9-23.
53. Leclercq R, Drugeon H, Coquemont M: Increased MICs of telithromycin in the presence of CO2 against strains of Streptococcus pneumoniae with erm (B): analysis of causative factors. 43rd ICAAC, 2003, Chicago.
54. Drugeon HB, Juvin M, Batard E, Moniot-Ville N, Bryskier A: Influence of CO2 on telithromycin MICs when Streptococcus pneumoniae isolates are resistant to macrolides by methylase production. 32nd ICAAC, 1992, Chicago.
55. Batard E, Juvin M, Moniot-Ville N, Jacqueline C, Bugnon D, Potel G, Drugeon HB: Determination of minimal inhibitory concentrations of telithromycin in ambient air and in CO2 for Streptococcus pneumoniae: an in vitro-in vivo correlation. 43rd ICAAC, 2003, Chicago.
56. Walsh F, Willcock J, Amyes S: High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae. J Antimicrob Chemother 2003; 52: 345-353.
57. Schmitz FJ, Petridou J, Milatovic D, Verhoef J, Fluit AC, Schwarz S: In vitro activity of new ketolides against macrolide-susceptible and -resistant Staphylococcus aureus isolates with defined resistance gene status. J Antimicrob Chemother 2002; 49: 580-582.
58. Schmitz FJ, Petridou J, Jagusch H, Astfalk N, Scheuring S, Schwarz S: Molecular characterization of ketolide-resistant erm(A)-carrying Staphylococcus aureus isolates selected in vitro by telithromycin, ABT-773, quinupristin and clindamycin. J Antimicrob Chemother 2002; 49: 611-617.
59. Besier S, Hunfeld KP, Giesser I, Schäfer V, Brade V, Wichelhaus TA: Selection of ketolide resistance in Staphylococcus aureus. Int J Antimicrob Agents 2003; 22: 87-88.
60. Hamilton-Miller JMT, Shah S: Patterns of phenotypic resistance to the macrolide-lincosamide-ketolide-streptogramin group of antibiotics in staphylococci. J Antimicrob Chemother 2000; 46: 941-949.
61. Jalava J, Kataja J, Seppälä H, Huovinen P: In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species. Antimicrob Agents Chemother 2001; 45: 789-793.
62. Morosini MI, Canton R, Loza E, Negri MC, Galan JC, Almaraz F, Baquero F: In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms. Antimicrob Agents Chemother 2001; 45: 2427-2431.
63. Sutcliffe J, Leclerq R: Mechanisms of resistance to macrolide, lincosamides, and ketolides. In: Schönfeld W, Kist HA (eds): Macrolide antibiotics. Birkhäuser Verlag, Basel 2002, pp 281-317.
64. Herrington JA, Frederici JA, Remy JM: Factors affecting the in vitro activity of moxifloxacin. In: Adam D, Finch R (eds): Moxifloxacin in practice. Maxim Medical, Oxford 2000, pp 73-79.
65. Berg HF, Tjhie JHT, Scheffer, G-J, Peeters MF, van Keulen PHJ, Kluytmans JAJW, Stobberingh EE: Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow release clarithromycin: a randomised, double-blind, placebo controlled study. Antimicrob Agents Chemother 2004; 48: 4183-4188.